Moderna To Submit For Emergency Use Of Coronavirus Vaccine; Study Results Show 94% Efficacy In Preventing Symptoms Among Infected Individuals
AP: Moderna asking U.S., European regulators to OK its virus shots
“Moderna Inc. said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens. … Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December. Across the Atlantic, British regulators also are assessing the Pfizer shot and another from AstraZeneca. Moderna created its shots with the U.S. National Institutes of Health and already had a hint they were working, but said it got the final needed results over the weekend that suggest the vaccine is more than 94% effective…” (Neergaard, 11/30).
Science: ‘Absolutely remarkable’ : No one who got Moderna’s vaccine in trial developed severe COVID-19
“Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago. More impressive still, Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among the vaccinees, but 30 in the placebo group…” (Cohen, 11/30).
Additional coverage of Moderna’s vaccine is available from Financial Times, New York Times, STAT, Wall Street Journal, and Washington Post.
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.